AI Analysis
AI-generated analysis. Always verify with the original filing.
DiaMedica reported a net loss of $32.8M in FY2025, a 34% increase from the prior year, driven by expanded clinical development activities, with free cash flow usage rising to $29.1M.
Key Takeaways
1Net loss increased to $32.8M from $24.4M in FY2024, primarily due to higher R&D spending linked to the ReMEDy2 trial's global expansion and clinical team growth.
2Free cash flow was -$29.1M, reflecting elevated operating losses partially offset by changes in operating assets and liabilities.
3Capital expenditures were minimal at $40K, consistent with reliance on third-party CDMOs rather than internal manufacturing infrastructure.
4The increase in cash used in operations stemmed from the wider net loss, though this was partially mitigated by non-cash adjustments and working capital changes.
5R&D costs rose significantly, driven by ongoing clinical trial execution and increased non-cash share-based compensation expenses.